Survey of Health Preferences in Cancer Patients (QALY-Cancer)
NCT ID: NCT03560817
Last Updated: 2019-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
198 participants
OBSERVATIONAL
2017-01-04
2019-06-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metastatic Breast Carcinoma and Women Sexual Quality of Life
NCT03408769
Descriptive Observational Study of the Evolution of the Lifestyle Alteration in Patients With Breast Cancer
NCT03712176
Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon
NCT01333735
Assessment the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request
NCT06415266
SexoMBC2 Non Interventional Study
NCT05577156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Quebec, no QALY calculation tool has been adapted to its linguistic and socio-cultural context, neither for its general population nor for a particular subpopulation, like patients with cancer.
The objectives will be to analyze the extent of the divergence in terms of health states utilities between the general population and patients with breast or colorectal cancer; to develop a QALY preference weights dataset for patients with cancer; to perform "mapping" with different health-related quality of life questionnaires by correlating SF6Dv2 with EQ-5D-5L, EORTC QLQ-C30 and FACT- G. The data will be collected with a self-administered online survey. Patients outcomes will be measured at the beginning of the chemotherapy treatment cycle and about 8 days after the start of chemotherapy. Health utilities will be measured with a hybrid method using the time-trade-off (TTO) and the discrete experimental choice (DCE) method using SF6Dv2 questionnaire for health states.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
breast cancer
No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
No interventions assigned to this group
colorectal cancer
No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* to reside in Quebec;
* have already had a chemotherapy treatment cycle;
* be on the eve of a new round of chemotherapy treatment;
* have breast or colorectal cancer
Exclusion Criteria
* not be able to complete a computer questionnaire;
* can not read or write in French;
* not be able to sign a consent form;
* the only treatment offered is surgery;
* presence of metastases to the brain;
* patient with delirium, psychosis or severe depression (i.e. chronic condition with treatment)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas G. Poder
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas G Poder, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-1490
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.